Prostaglandin H synthase (PGHS) is a an integral membrane protein which converts arachidonic acid, an essential fatty acid, into the initial enzymatic products, PGG2 and PGH2 by means of a free radical mechanism. Prostaglandins initiate numerous cell and tissue responses including vasodilation, vaso-constriction, blood clotting, cell proliferation and inflammation. Nonsteroidal anti-inflammatory drugs (NSAIDs), which inhibit prostanoid biosynthesis by targeting the cyclooxygenase activity of PGHS, are used to treat certain symptoms of inflammatory and cardiovascular diseases. The prostanoids are also involved in pathophysiology of a number of diseases including atherosclerosis, rheumatoid arthritis, and cancer; in the latter, aspirin is now a proven anticancer prophylaxis. Two isoforms of PGHS have been discovered: PGHS-1 is involved in homeostatic or """"""""house- keeping"""""""" prostaglandin biosynthesis while PGHS-2 induced by cytokines during inflammatory events. We are continuing our efforts to determine the X-ray crystal structure of PGHS-1 to the highest resolution possible. We have solved the structure of PGHS-1 to 3.1 A resolution, have built an atomic model of the enzyme, and have characterized PGHS-1 complexes a=with four NSAIDs: bromoaspirin, flurbiprofen, iodosuprofen and iodoindomethacin. We are beginning to collect high resolution data (2.8 A) at the synchrotron radiation facilities which will require further technological development such as the flash-freezing of membrane protein crystals. We will continue our study on the nature of enzyme-drug interactions and structure-function relationships, with particular focus on the mechanisms of substrate and NSAID interactions as well as the mode of targeting the ER membrane. This would involve analyzing ligand-induced conformational changes in PGHS-1, and characterizing ligand complexes of PGHS-1 and PGHS-2 by means of a complementary series of enzymological, EPR/ENDOR spectroscopic and X-ray diffraction experiments. With the discovery of an inducible from of PGHS, questions arise about the functional differences between PGHS-1 and PGHS-2. We have predicted the structure of PGHS-2, using the known sequences and the PGHS-1 as a model, and are analyzing the structure-function relationships in this new isozyme. Crystallization trial for mouse PGHS-2 are underway.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL056773-04
Application #
6030763
Study Section
Biophysical Chemistry Study Section (BBCB)
Project Start
1996-07-01
Project End
2001-06-30
Budget Start
1999-07-01
Budget End
2001-06-30
Support Year
4
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Michigan State University
Department
Biochemistry
Type
Schools of Arts and Sciences
DUNS #
193247145
City
East Lansing
State
MI
Country
United States
Zip Code
48824
Qin, Ling; Mills, Denise A; Hiser, Carrie et al. (2007) Crystallographic location and mutational analysis of Zn and Cd inhibitory sites and role of lipidic carboxylates in rescuing proton path mutants in cytochrome c oxidase. Biochemistry 46:6239-48
Harman, Christine A; Turman, Melissa V; Kozak, Kevin R et al. (2007) Structural basis of enantioselective inhibition of cyclooxygenase-1 by S-alpha-substituted indomethacin ethanolamides. J Biol Chem 282:28096-105
Wada, Masayuki; DeLong, Cynthia J; Hong, Yu H et al. (2007) Enzymes and receptors of prostaglandin pathways with arachidonic acid-derived versus eicosapentaenoic acid-derived substrates and products. J Biol Chem 282:22254-66
Harman, Christine A; Rieke, Caroline Jill; Garavito, R Michael et al. (2004) Crystal structure of arachidonic acid bound to a mutant of prostaglandin endoperoxide H synthase-1 that forms predominantly 11-hydroperoxyeicosatetraenoic acid. J Biol Chem 279:42929-35
Garavito, R Michael; Mulichak, Anne M (2003) The structure of mammalian cyclooxygenases. Annu Rev Biophys Biomol Struct 32:183-206
Garavito, R Michael; Malkowski, Michael G; DeWitt, David L (2002) The structures of prostaglandin endoperoxide H synthases-1 and -2. Prostaglandins Other Lipid Mediat 68-69:129-52
Lin, Henry J; Lakkides, Karen M; Keku, Temitope O et al. (2002) Prostaglandin H synthase 2 variant (Val511Ala) in African Americans may reduce the risk for colorectal neoplasia. Cancer Epidemiol Biomarkers Prev 11:1305-15
Malkowski, M G; Thuresson, E D; Lakkides, K M et al. (2001) Structure of eicosapentaenoic and linoleic acids in the cyclooxygenase site of prostaglandin endoperoxide H synthase-1. J Biol Chem 276:37547-55
Garavito, R M; Ferguson-Miller, S (2001) Detergents as tools in membrane biochemistry. J Biol Chem 276:32403-6
Thuresson, E D; Lakkides, K M; Rieke, C J et al. (2001) Prostaglandin endoperoxide H synthase-1: the functions of cyclooxygenase active site residues in the binding, positioning, and oxygenation of arachidonic acid. J Biol Chem 276:10347-57

Showing the most recent 10 out of 16 publications